ADB-4en-PINACA
Chemical compound
From Wikipedia, the free encyclopedia
ADB-4en-PINACA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products,[1] first appearing in early 2021. It is a reasonably potent cannabinoid agonist in vitro but has not been so widely sold as related compounds such as ADB-PINACA and MDMB-4en-PINACA.[2][3][4][5]
Legal status
- CA: Schedule II
- DE: NpSG (Industrial and scientific use only)
- UK: Class B
- US: Schedule I
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H26N4O2 |
| Molar mass | 342.443 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Legality
In the United States, the DEA has temporarily placed ADB-4en-PINACA into Schedule I status starting on December 12, 2023, for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file to permanent placement the temporary Schedule I order will expire on December 12, 2025.[6]